Cost-Effectiveness between Double and Single Fecal Immunochemical Test(s) in a Mass Colorectal Cancer Screening
Table 2
Odds ratio (OR) and 95% confidence interval (CI) of detection of colorectal cancer (CRC) and adenoma using colonoscopy as a gold standard by gender, age group, and fecal immunochemical test (FIT) status in the Jiashan mass CRC screening program in China, 2007–2009.
Gender/age
FIT
Colonoscopy participant
CRC
OR1 (95% CI)
OR2 (95% CI)
OR3 (95% CI)
Adenoma
OR1 (95% CI)
OR2 (95% CI)
OR3 (95% CI)
(%)
(), %
Men <55
FIT1
182
1 (100.0)
1.00
1.0
37 (), 75.5
1.00
1.0
FIT2
162
1 (100.0)
1.12 (0.07–18.12)
1.00
1.0
25 (), 51.0
0.72 (0.41–1.25)
1.00
1.0
Both
54
1 (100.0)
3.42 (0.21–55.53)
3.04 (0.19–49.42)
1.0
13 (), 26.5
1.24 (0.60–2.56)
1.74 (0.82–3.70)
1.0
Either
294
1 (100.0)
0.62 (0.38–9.94)
0.55 (0.03–8.84)
1.0
49 (), 100.0
0.78 (0.49–1.26)
1.10 (0.65–1.85)
1.0
Men ≥55
FIT1
245
19 (86.4)
1.00
15.23 (2.02–114.75)
65 (), 72.2
1.00
1.42 (0.89–2.24)
FIT2
196
13 (59.1)
0.85 (0.41–1.76)
1.00
11.44 (1.48–88.40)
48 (), 53.3
0.90 (0.58–1.38)
1.00
2.10 (1.23–3.58)
Both
73
10 (45.5)
1.89 (0.84–4.27)
2.23 (0.93–5.35)
8.41 (1.04–67.87)
23 (), 25.6
1.27 (0.72–2.25)
1.42 (0.79–2.56)
1.45 (0.66–3.22)
Either
368
22 (100.0)
0.76 (0.40–1.43)
0.90 (0.44–1.82)
18.63 (2.50–139.05)
90 (), 100.0
0.90 (0.62–1.30)
1.00 (0.67–1.49)
1.62 (1.10–2.39)
Women <55
FIT1
257
3 (75.0)
1.00
1.0
16 (), 64.0
1.00
1.0
FIT2
198
2 (50.0)
0.86 (0.14–5.22)
1.00
1.0
14 (), 56.0
1.15 (0.55–2.41)
1.00
1.0
Both
57
1 (25.0)
1.51 (0.15–14.81)
1.75 (0.16–19.66)
1.0
5 (), 20.0
1.45 (0.51–4.13)
1.26 (0.44–3.67)
1.0
Either
398
4 (100.0)
0.86 (0.19–3.87)
1.00 (0.18–5.48)
1.0
25 (), 100.0
1.01 (0.53–1.93)
0.88 (0.45–1.74)
1.0
Women ≥55
FIT1
237
10 (83.3)
1.00
3.73 (1.01–13.72)
30 (), 63.8
1.00
2.18 (1.16–4.12)
FIT2
198
8 (66.7)
0.96 (0.37–2.47)
1.00
4.13 (0.87–19.68)
30 (), 63.8
1.23 (0.71–2.13)
1.00
2.35 (1.20–4.58)
Both
66
6 (50.0)
2.27 (0.79–6.50)
2.38 (0.79–7.12)
5.60 (0.65–47.98)
13 (), 27.7
1.69 (0.83–3.47)
1.37 (0.67–2.82)
2.55 (0.85–7.66)
Either
369
12 (100.0)
0.76 (0.32–1.80)
0.80 (0.32–1.99)
3.31 (1.06–10.36)
47 (), 100.0
1.01 (0.62–1.64)
0.82 (0.50–1.34)
2.18 (1.31–3.62)
Men All age
FIT1
432
20 (87.0)
1.0
1.0
102 (), 73.4
1.0
1.0
FIT2
358
14 (60.1)
0.84 (0.42–1.69)
1.0
1.0
73 (), 52.5
0.83 (0.59–1.16)
1.0
1.0
Both
127
11 (47.8)
1.95 (0.91–4.19)
2.33 (1.03–5.28)
1.0
36 (), 25.9
1.28 (0.82–2.00)
1.54 (0.97–2.46)
1.0
Either
663
23 (100.0)
0.74 (0.40–1.37)
0.88 (0.45–1.74)
1.0
139 (), 100.0
0.86 (0.64–1.15)
1.04 (0.75–1.42)
1.0
Women All age
FIT1
494
13 (81.3)
1.0
0.56 (0.27–1.13)
46 (), 63.9
1.0
0.33 (0.23–0.48)
FIT2
396
10 (62.5)
0.96 (0.42–2.21)
1.0
0.64 (0.28–1.45)
44 (), 61.1
1.22 (0.79–1.88)
1.0
0.49 (0.33–0.73)
Both
123
7 (43.8)
2.23 (0.87–5.72)
2.33 (0.87–6.26)
0.64 (0.24–1.70)
18 (), 25.0
1.67 (0.93–3.00)
1.37 (0.76–2.47)
0.43 (0.23–0.82)
Either
767
16 (100)
0.79 (0.38–1.65)
0.82 (0.37–1.83)
0.59 (0.31–1.13)
72 (), 100.0
1.01 (0.68–1.49)
0.83 (0.56–1.23)
0.39 (0.29–0.53)
Total
FIT1
926
33 (84.6)
1.0
—
148 (), 70.1
1.0
—
FIT2
754
24 (61.5)
0.89 (0.52–1.52)
1.0
—
117 (), 55.5
0.97 (0.74–1.26)
1.0
—
Both
250
18 (46.2)
2.10 (1.16–3.80)
2.36 (1.26–4.43)
—
54 (), 25.6
1.45 (1.02–2.05)
1.50 (1.05–2.15)
—
Either
1,430
39 (100.0)
0.76 (0.47–1.22)
0.85 (0.51–1.43)
—
211 (), 100.0
0.91 (0.72–1.14)
0.94 (0.74–1.21)
—
FIT1, the first FIT; FIT2, the second FIT; OR1 using FIT1 as reference and OR2 using FIT2 as reference; OR3 using men with age <55 who completed FIT1 as reference, OR3 using men with age <55 who completed FIT2 as reference, OR3 using men with age <55 who completed both FIT1 and FIT2 as reference, OR3 using men with age <55 who completed either FIT1 or FIT2 as reference, OR3 using women with age <55 who completed FIT1 as reference, OR3 using women with age <55 who completed FIT2 as reference, OR3 using women with age <55 who completed both FIT1 and FIT2 as reference, and OR3 using women with age <55 who completed either FIT1 or FIT2 as reference. : the number of advanced adenomas.
